Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Date
2019
Author
KAYNAR, LEYLAGÜL
BOLAMAN, ALİ ZAHİT
Teke, Havva Uskudar
Atalay, Figen
ALTUNTAŞ, FEVZİ
Salihoglu, Ayse
BEKSAÇ, MERAL
Seval, Guldane Cengiz
PAYDAŞ, SEMRA
Tuglular, Tulin Firatli
ARSLAN, ÖNDER
GÖKER, HAKAN
Yurttas, Nurgul Ozgur
GÜRMAN, GÜNHAN
Cakar, Merih Kizil
Albayrak, Murat
Kabukcu, Sibel Hacioglu
YILMAZ, MEHMET
TOPÇUOĞLU, PERVİN
DEMİR, AHMET MUZAFFER
SÖNMEZ, MEHMET
PEHLİVAN, MUSTAFA
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/24656
https://doi.org/10.1016/j.clml.2019.09.402
Collections